
↘️ Amgen (AMGN): Shares of the biotechnology company, a major contributor to the Dow, shed more than 5% premarket after the Swiss drugmaker Novartis (CH:NOVN) said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial.























